Annualized Relapse Rate (ARR) of 0.07 observed for all patients on Phase 2 trial ECTRIMS data review conference call to be held [...]
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS), a highly debilitating [...]
Late-breaking Phase II primary endpoint data for investigational therapy evobrutinib, the first oral BTK inhibitor to show [...]
Dear Advocates, OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression over Five Years in [...]
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents [...]
Researchers have discovered a new subtype of multiple sclerosis (MS), providing a better understanding of the disease and potentially [...]
Researchers have apparently found a way to help predict multiple sclerosis disease progression one year after an initial [...]
When the following headline in the Australian newspaper the Herald Sun caught my eye recently, I was cautiously intrigued: “Doctors [...]
PDF ROCKLAND, Mass., July 30, 2018 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and [...]
Researchers say if a person with multiple sclerosis is irritable or anxious, it can make overcoming the obstacles of their disease much [...]